Investors and Media
Investor Relations
Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies to degrade disease-causing proteins.
Arvinas uses their proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.
Corporate Presentation
We Create PROteolysis TArgeting Chimeras
We are engineering an expansive pipeline of proteolysis targeting chimeras, or PROTACs, designed to harness the body’s own natural protein disposal system (the ubiquitin proteasome system) to selectively and efficiently degrade and remove disease-causing proteins.
NASDAQ: ARVN
Minimum 15 minutes delayed. Source: LSEG
-
Print Page
-
RSS Feeds
-
Email Alerts
-
Search